Internet group Tencent has led a series B round for China-based medical device developer Raysight Medical sized at almost RMB300m ($46.3m), DealStreetAsia has reported, citing a company statement.
Venture capital firm Matrix Partners China also backed the round, which was facilitated by investment bank China Renaissance.
Raysight develops medical systems used in the treatment of cardiovascular diseases and will utilise the funding to further develop intelligent platform technology as well as commercialising its products and strengthening its partnerships.
The company closed an undisclosed amount of series A funding from Matrix Partners China in 2019 and increased its total funding to $14.1m in a $7m series A-plus round in June 2020 that was led by China Growth Capital and which included Matrix Partners China and Greenriver Investment.